Rainbownewsline

The Asia Pacific stem cell manufacturing market is projected to grow at the highest CAGR during the forecast period, mainly due to increasing awareness of stem cell transplants and a large number of pipeline products.

Stem Cell Manufacturing Market in terms of revenue was estimated to be worth $12.7 Billion in 2023 and is poised to reach $21.8 Billion by 2028, growing at a CAGR of 11.3% from 2023 to 2028 according to a new report by MarketsandMarkets™. Some of the prominent factors driving the growth of this market are increasing funding of stem cell research and increasing demand for stem cell-based therapies are boosting the growth of the market. However, ethical concerns and high costs of research and manufacturing can hamper the market growth.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=70743403

In the near future, the stem cell manufacturing industry is poised to experience unprecedented growth and innovation, revolutionizing healthcare and regenerative medicine. Rapid advancements in biotechnology, automation, and personalized medicine will play pivotal roles in transforming stem cell production and application. The advent of cutting-edge techniques, like induced pluripotent stem cells (iPSCs) and gene editing technologies, will enable the creation of patient-specific stem cell lines, revolutionizing transplantation and reducing the risk of immune rejection. Automated bioreactors and 3D bioprinting will streamline the manufacturing process, ensuring scalability and cost-effectiveness. 

Consumables products accounted for the largest share of the stem cell manufacturing market.

Among the products, the stem cell manufacturing market is segmented into instruments, consumables, and stem cell lines. In 2023, the consumables products segment accounted for the largest share of the stem cell manufacturing market. Growth in this market segment can be attributed to increasing research of stem cell-based therapies, and increasing purchase and demand of consumables are expected to form the fastest growth segment in the stem cell manufacturing market.

The cell & tissue banking applications segment is the fastest-growing segment of the stem cell manufacturing market.

In 2023, the cell & tissue banking applications segment accounted for the fastest-growing share of the application segment of the stem cell manufacturing market. Market growth can largely be attributed to the potential development of advanced storage methodologies. The market is also driven by increasing public demand for cord blood stem cell banking and rising awareness regarding the advantages of stem cell preservation.

Asia Pacific: The fastest-growing region in the stem cell manufacturing market.

The Asia Pacific stem cell manufacturing market is projected to grow at the highest CAGR during the forecast period, mainly due to increasing awareness of stem cell transplants and a large number of pipeline products. The Asian market has also garnered significant attention from global players due to the increased focus on personalized medicine, driving the demand for stem cell-based therapies.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=70743403

Key Market Players:

The market for stem cell manufacturing is highly fragmented, with key players strategizing to capture a majority of the market. Prominent players in the market are Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Lonza Group (Switzerland), Danaher Corporation (US), Sartorius AG (Germany), Becton, Dickinson, and Company (US), Eppendorf AG (Germany), Corning Inc. (US), Bio-Rad Laboratories (US),  Takara Bio Group (Japan), Fujifilm Holdings Corporation (Japan), Getinge AB (Sweden), Terumo Corporation (Japan), Bio-Techne Corporation (US), HiMedia Laboratories (India), StemCell Technologies, Inc. (Canada), Miltenyi Biotec GmBH (Germany), PromoCell (Germany), Anterogen Co. Ltd. (South Korea), CellGenix GmBH (India), Pluristem Therapeutics Inc. (Israel), Daiichi Sankyo (Japan), Organogenesis Holdings Inc. (US), Vericel Corporation (US), and American Cryostem Corporation (US).

Recent Developments:

• In April 2023, U.S. Food and Drug Administration approved Omisirge (omidubicel), a substantially modified allogeneic (donor) cord blood-based cell therapy to quicken the recovery of neutrophils (a subset of white blood cells) in the body and reduce the risk of infection. Developments like this are increasing the demand for stem cell therapies and culture media.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=70743403

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/stem-cell-manufacturing-market-70743403.html